James Theuerle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James Theuerle has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Omar Farouque
The University of Melbourne Clinical School, Austin Health, Department of Cardiology, Melbourne, Victoria, Australia
8 shared publications - Ali Al-Fiadh
Department of Cardiology, Austin Health, Heidelberg, VIC, Australia
5 shared publications Anoop N. Koshy
5 shared publications- Louise M. Burrell
Department of Medicine, The University of Melbourne, Austin Health, Victoria, Australia
4 shared publications - Julian Yeoh
Department of Cardiology, Austin Health, Melbourne, Vic, Australia
3 shared publications - Matias B. Yudi
Department of Cardiology, The University of Melbourne Clinical School, Austin Health, Melbourne, Victoria, Australia
3 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Elsevier in SSRN Electronic Journal
Sex Differences in Mortality and Readmission Following Hospitalisation for Heart Failure: A Statewide Cohort Study
BackgroundHeart failure (HF) is a leading cause of hospitalisation in Australia. Although sex differences in HF prognosis are recognised, population-level data describing outcomes across multiple time points remain limited.MethodsUsing administrative data from the Victorian Department of Health, we identified a cohort of adults with an index HF hospitalisation between 1st January 2019 and 31st December 2022. Logistic regression models assessed associations between sex and in-hospital, 30-day and 180-day all-cause mortality and readmission, adjusting for age, Charlson Comorbidity Index, socioeconomic status, Aboriginal and Torres Strait Islander status, and hospital type. Interaction terms were used to examine whether associations were modified by age, comorbidity burden and hospital type.ResultsAmong 92,581 patients hospitalised with HF, 52% were male, with females older than males (females: mean age 79.1 years, SD=13.2 vs males: mean age 75.7 years, SD=13.7, p<0.0001). After adjustment, male sex was associated with higher mortality at all time points: in-hospital (OR 1.09, 95% CI 1.04-1.14), 30-day (OR 1.12, 95% CI 1.05-1.21),180-day (OR 1.18, 95% CI 1.13-1.23), and higher 180-day readmission (OR 1.07, 95% CI 1.04-1.11).Sex differences in readmission were modified by age, comorbidity burden and hospital type; sex differences in 180-day mortality were modified by comorbidity burden.ConclusionsMale sex was independently associated with higher mortality across all time points and higher longer-term readmission following HF hospitalisation. These findings highlight heterogeneity in sex differences in HF outcomes, modified by age, comorbidity burden and hospital type. This may inform sex-specific approaches to post-discharge risk stratification and care.
- 23 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSex Differences in Mortality and Readmission Following Hospitalisation for Heart Failure: A Statewide Cohort Study
BackgroundHeart failure (HF) is a leading cause of hospitalisation in Australia. Although sex differences in HF prognosis are recognised, population-level data describing outcomes across multiple time points remain limited.MethodsUsing administrative data from the Victorian Department of Health, we identified a cohort of adults with an index HF hospitalisation between 1st January 2019 and 31st December 2022. Logistic regression models assessed associations between sex and in-hospital, 30-day and 180-day all-cause mortality and readmission, adjusting for age, Charlson Comorbidity Index, socioeconomic status, Aboriginal and Torres Strait Islander status, and hospital type. Interaction terms were used to examine whether associations were modified by age, comorbidity burden and hospital type.ResultsAmong 92,581 patients hospitalised with HF, 52% were male, with females older than males (females: mean age 79.1 years, SD=13.2 vs males: mean age 75.7 years, SD=13.7, p<0.0001). After adjustment, male sex was associated with higher mortality at all time points: in-hospital (OR 1.09, 95% CI 1.04-1.14), 30-day (OR 1.12, 95% CI 1.05-1.21),180-day (OR 1.18, 95% CI 1.13-1.23), and higher 180-day readmission (OR 1.07, 95% CI 1.04-1.11).Sex differences in readmission were modified by age, comorbidity burden and hospital type; sex differences in 180-day mortality were modified by comorbidity burden.ConclusionsMale sex was independently associated with higher mortality across all time points and higher longer-term readmission following HF hospitalisation. These findings highlight heterogeneity in sex differences in HF outcomes, modified by age, comorbidity burden and hospital type. This may inform sex-specific approaches to post-discharge risk stratification and care.
- Open Access
- 22 September 2026
- Published by Elsevier in Heart, Lung and Circulation
Implementing a Same-Day PCI Protocol in Australia: Impact on Uptake, Safety, and Quality of Life
- 22 September 2026
- Published by Elsevier in Heart, Lung and Circulation
Open AccessImplementing a Same-Day PCI Protocol in Australia: Impact on Uptake, Safety, and Quality of Life
- 29 June 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19  (6) , e272375
Late diagnosis of late onset Fabry disease
A male in his 50s initially presented with left ventricular hypertrophy (LVH) identified on transthoracic echocardiogram. He was diagnosed with hypertrophic cardiomyopathy without any further investigations. He later presented in his 70s with decompensated heart failure. A cardiac MRI was performed that demonstrated extensive scarring, and the patient was labelled with a presumptive diagnosis of cardiac amyloidosis. An endomyocardial biopsy demonstrated extensive myocyte hypertrophy and fibrosis but was non-diagnostic in identifying a cause of the LVH. Genetic testing revealed that the patient had a genetic variant in the GLA gene, which encodes for the α-galactosidase A enzyme that is known to be associated with adult onset of Fabry disease. This case highlights the importance of early incorporation of genetic screening and advanced imaging modalities in patients presenting with LVH.
- 29 June 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19  (6) , e272375
Late diagnosis of late onset Fabry disease
A male in his 50s initially presented with left ventricular hypertrophy (LVH) identified on transthoracic echocardiogram. He was diagnosed with hypertrophic cardiomyopathy without any further investigations. He later presented in his 70s with decompensated heart failure. A cardiac MRI was performed that demonstrated extensive scarring, and the patient was labelled with a presumptive diagnosis of cardiac amyloidosis. An endomyocardial biopsy demonstrated extensive myocyte hypertrophy and fibrosis but was non-diagnostic in identifying a cause of the LVH. Genetic testing revealed that the patient had a genetic variant in the GLA gene, which encodes for the α-galactosidase A enzyme that is known to be associated with adult onset of Fabry disease. This case highlights the importance of early incorporation of genetic screening and advanced imaging modalities in patients presenting with LVH.
- Open Access
- 15 May 2026
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 35  (6) , 821-831
Quality of Life and Function After TAVI in Adults Aged ≥90 Years: Frailty and Multimorbidity Matter
- 15 May 2026
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 35  (6) , 821-831
Open AccessQuality of Life and Function After TAVI in Adults Aged ≥90 Years: Frailty and Multimorbidity Matter
- Open Access
- 30 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14  (15) , 5371
Nurse-Led, Remote Optimisation of Guideline-Directed Medical Therapy in Patients with Heart Failure and Reduced Ejection Fraction Across Australia
Background/Objectives: Guidelines recommend patients with heart failure with reduced ejection fraction (HFrEF) receive four-pillar heart failure (4P-HF) therapy, which significantly reduces cardiac morbidity and mortality. However, implementing these guidelines effectively into clinical practice remains challenging. Methods: Patients with HFrEF on submaximal 4P-HF therapy were identified from a large, multicentre Cardiology network database using a natural language processing tool, supported by manual file review. A nurse-led, remotely delivered, medication uptitration program aimed to optimise therapy in this real-world cohort. Results: The final cohort included 2004 patients with a mean age of 72.7 ± 11.6 years. Utilisation of 4P-HF increased from 11.1% at baseline to 49.8% post intervention, and each individual medication class increased significantly post intervention (all p < 0.001). The largest increase was observed with the use of sodium–glucose cotransporter 2 inhibitors, which rose from 17.3% to 73.9%, followed by mineralocorticoid receptor antagonists (51.6% to 65.7%), beta-blockers (88.4% to 97.0%), and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor blocker–neprilysin inhibitors (89.8% to 96.4%). In patients on submaximal therapy, barriers were documented in all cases. Following medication optimisation, left ventricular ejection function (LVEF) improved significantly (38.5% ± 10.8% vs. 42.5% ± 11.7, p < 0.001). Conclusions: This nurse-led, remotely delivered, medication optimisation program significantly improved the adoption of 4P-HF therapy and LVEF in patients with HFrEF. The program demonstrates a practical, scalable solution for the optimisation of HFrEF therapy across a large healthcare network.
- 30 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14  (15) , 5371
Open AccessNurse-Led, Remote Optimisation of Guideline-Directed Medical Therapy in Patients with Heart Failure and Reduced Ejection Fraction Across Australia
Background/Objectives: Guidelines recommend patients with heart failure with reduced ejection fraction (HFrEF) receive four-pillar heart failure (4P-HF) therapy, which significantly reduces cardiac morbidity and mortality. However, implementing these guidelines effectively into clinical practice remains challenging. Methods: Patients with HFrEF on submaximal 4P-HF therapy were identified from a large, multicentre Cardiology network database using a natural language processing tool, supported by manual file review. A nurse-led, remotely delivered, medication uptitration program aimed to optimise therapy in this real-world cohort. Results: The final cohort included 2004 patients with a mean age of 72.7 ± 11.6 years. Utilisation of 4P-HF increased from 11.1% at baseline to 49.8% post intervention, and each individual medication class increased significantly post intervention (all p < 0.001). The largest increase was observed with the use of sodium–glucose cotransporter 2 inhibitors, which rose from 17.3% to 73.9%, followed by mineralocorticoid receptor antagonists (51.6% to 65.7%), beta-blockers (88.4% to 97.0%), and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor blocker–neprilysin inhibitors (89.8% to 96.4%). In patients on submaximal therapy, barriers were documented in all cases. Following medication optimisation, left ventricular ejection function (LVEF) improved significantly (38.5% ± 10.8% vs. 42.5% ± 11.7, p < 0.001). Conclusions: This nurse-led, remotely delivered, medication optimisation program significantly improved the adoption of 4P-HF therapy and LVEF in patients with HFrEF. The program demonstrates a practical, scalable solution for the optimisation of HFrEF therapy across a large healthcare network.
- Open Access
- 27 January 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9  (2) , ytaf042
Inferior ST-elevation myocardial infarction due to a thrombosed sinus of Valsalva aneurysm
- 27 January 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9  (2) , ytaf042
Open AccessInferior ST-elevation myocardial infarction due to a thrombosed sinus of Valsalva aneurysm
- 9 December 2024
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 41  (4) , 659-667
Diagnosis of bicuspid aortic valves: CT vs. TTE
Bicuspid aortic valfves (BAV) are a relatively common cardiac abnormality, with an associated risk of aortic stenosis, aortic regurgitation and aortopathy. First-line diagnosis is via transthoracic echocardiography (TTE), which may be impacted by valve calcification and operator variability. Electrocardiogram-gated computed tomography (CT) offers an alternative form of assessment. The aim of this systematic review and meta-analysis is to evaluate the diagnostic performance of TTE versus CT for BAV. Eligible studies were retrieved from inception through to March 2024 on OVID Medline, Embase and Cochrane Library. All primary studies regarding the diagnostic performance of TTE and/or CT with regards to BAV were included. The QUADAS-2 tool was utilized for quality assessment. Sensitivity and specificity data were statistically analyzed. Of 4698 records, 19 were eligible for inclusion, and 16 had sufficient data for inclusion in the meta-analysis. There was only data regarding TTE vs. retrospectively ECG-gated CT. There was a significant difference between the sensitivity of retrospectively ECG-gated cardiac CT (95.5% (95% CI: [91.3–97.5%]) and TTE (79.7%, 95% CI: [71.6–86.0%]) for identifying BAV. The specificity was high and not significantly different for both CT and TTE (96%, 95% CI: [92.5–98.2%] and 91.3%, 95% CI: [87.3–93.8%], respectively). Retrospectively ECG-gated CT demonstrates greater sensitivity for diagnosis of BAV compared to TTE. Both modalities are non-invasive and demonstrate good specificity for excluding BAV. Given that CT scans are easily accessible, they offer a reasonable second-line investigation for diagnosis of BAV when an initial TTE is inconclusive.
- 9 December 2024
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 41  (4) , 659-667
Diagnosis of bicuspid aortic valves: CT vs. TTE
Bicuspid aortic valfves (BAV) are a relatively common cardiac abnormality, with an associated risk of aortic stenosis, aortic regurgitation and aortopathy. First-line diagnosis is via transthoracic echocardiography (TTE), which may be impacted by valve calcification and operator variability. Electrocardiogram-gated computed tomography (CT) offers an alternative form of assessment. The aim of this systematic review and meta-analysis is to evaluate the diagnostic performance of TTE versus CT for BAV. Eligible studies were retrieved from inception through to March 2024 on OVID Medline, Embase and Cochrane Library. All primary studies regarding the diagnostic performance of TTE and/or CT with regards to BAV were included. The QUADAS-2 tool was utilized for quality assessment. Sensitivity and specificity data were statistically analyzed. Of 4698 records, 19 were eligible for inclusion, and 16 had sufficient data for inclusion in the meta-analysis. There was only data regarding TTE vs. retrospectively ECG-gated CT. There was a significant difference between the sensitivity of retrospectively ECG-gated cardiac CT (95.5% (95% CI: [91.3–97.5%]) and TTE (79.7%, 95% CI: [71.6–86.0%]) for identifying BAV. The specificity was high and not significantly different for both CT and TTE (96%, 95% CI: [92.5–98.2%] and 91.3%, 95% CI: [87.3–93.8%], respectively). Retrospectively ECG-gated CT demonstrates greater sensitivity for diagnosis of BAV compared to TTE. Both modalities are non-invasive and demonstrate good specificity for excluding BAV. Given that CT scans are easily accessible, they offer a reasonable second-line investigation for diagnosis of BAV when an initial TTE is inconclusive.